PD317 - MYOPENIA IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF MORPHOFUNCTIONAL ASSESSMENT

PD317

MYOPENIA IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF MORPHOFUNCTIONAL ASSESSMENT

M. GONZALEZ PACHECO^1,*, A. Martínez Hartmann¹, A. Lara Barea¹, F. J. Vílchez López¹, M. D. M. Roca Rodríguez¹

¹Department of Endocrinology and Nutrition, Puerta del Mar University Hospital, Cádiz, Spain

Rationale: Patients with inflammatory bowel disease (IBD) are at risk of myopenia; we investigated whether appendicular skeletal muscle mass index (ASMMI) is associated with morphofunctional parameters to improve early nutritional assessment.

Methods: This retrospective observational study included patients with IBD attended at Puerta del Mar University Hospital between January 2023 and September 2025. Clinical, anthropometric, and morphofunctional assessment variables were analysed. Myopenia was defined according to ASMMI following EWGSOP2 criteria. Associations were assessed using Spearman’s correlation, and median differences according to myopenia status were compared using the Mann–Whitney U test.

Results: A total of 26 patients were included; 48% were women, the median age was 32 years, 65.4% had Crohn’s disease, and 34.6% had ulcerative colitis. Overall, 63% presented myopenia. Compared with patients without myopenia, those with myopenia showed lower body cell mass (20.8 vs 26.8 kg; p=0.020), lower fat-free mass (40 vs 52.8 kg; p=0.006), and lower muscle ultrasound area (3.9 vs 5.3 cm²; p=0.003). ASMMI was correlated with muscle ultrasound area (r=0.599; p=0.003) and handgrip strength (r=0.805; p<0.001).

Conclusion: Myopenia in patients with IBD is associated with an impaired morphofunctional profile. Combined assessment using BIA, ultrasound, and dynamometry may help identify early loss of muscle mass and function and support comprehensive nutritional assessment in these patients.

Disclosure of Interest: None declared